Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Ren W, Zhang J, Chen Y, Wen M, Su Y, Zhao Y, Lu S, Wu J. Evaluation of Coagulation, Fibrinolysis and Endothelial Biomarkers in Cirrhotic Patients With or Without Portal Venous Thrombosis. Clin Appl Thromb Hemost 2021;26:1076029620982666. [PMID: 33356499 PMCID: PMC7768576 DOI: 10.1177/1076029620982666] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open

For:	Ren W, Zhang J, Chen Y, Wen M, Su Y, Zhao Y, Lu S, Wu J. Evaluation of Coagulation, Fibrinolysis and Endothelial Biomarkers in Cirrhotic Patients With or Without Portal Venous Thrombosis. Clin Appl Thromb Hemost 2021;26:1076029620982666. [PMID: 33356499 PMCID: PMC7768576 DOI: 10.1177/1076029620982666] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open

Number

Cited by Other Article(s)

Wu Z, Xiao Y, Qi Z, Guo T, Tong H, Wang Y. Effect of factor VIII and FVIII/PC ratio on portal vein thrombosis in liver cirrhosis: a systematic review and meta‑analysis. BMC Gastroenterol 2024;24:320. [PMID: 39300356 PMCID: PMC11411769 DOI: 10.1186/s12876-024-03399-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2024] [Accepted: 09/02/2024] [Indexed: 09/22/2024] Open

Ren H, Sun Y, Li Y, Yuan X, Jiang B, Zhang W, Liu G, Lu P. Potential Mechanism of Platelet GPIIb/IIIa and Fibrinogen on Retinal Vein Occlusion. Curr Eye Res 2024;49:731-741. [PMID: 38482878 DOI: 10.1080/02713683.2024.2327055] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 03/03/2024] [Indexed: 06/26/2024]

Abstract

PURPOSE

To explore the role of coagulation and fibrinolytic factors, and the potential mechanism of platelet aggregation in the pathogenesis of retinal vein occlusion.

METHODS

Coagulation and fibrinolytic parameters in patients with retinal vein occlusion were determined using hemagglutinin and HISCL-5000. Relationships between these elevated parameters and factors representing typical clinical manifestations of retinal vein occlusion were examined, and these parameters were analyzed using a STRING database to indicate the potential role of platelet aggregation. Platelet glycoprotein IIb/IIIa (GPIIb/IIIa) levels were evaluated by flow cytometry after antiplatelet treatment in patients and mouse models. Furthermore, the GPIIb/IIIa ligand fibrinogen in peripheral blood and retina of mouse models was assessed by the turbidimetric method and real-time PCR, respectively.

RESULTS

In patients, significant increases in peripheral blood fibrinogen and GPIIb/IIIa levels were observed (p = 0.0040, p < 0.0001, respectively). A positive correlation was observed between macular thickness (MT) and both fibrinogen and GPIIb/IIIa (r = 0.4528, p = 0.0063; r = 0.3789, p = 0.0427, respectively). After intravitreal injections of anti-vascular endothelial growth factor drugs, a significant reduction in fibrinogen levels was observed (p = 0.0072). In addition, the use of antiplatelet drugs resulted in a significant decrease in GPIIb/IIIa (p < 0.0001). In a mouse model, antiplatelet therapy significantly reduced both peripheral blood and retina fibrinogen levels and the overall rate of vein occlusion 3 days after occlusion (p < 0.0005). In addition, the reduction in GPIIb/IIIa levels after antiplatelet therapy was remarkable.

CONCLUSION

Fibrinogen and GPIIb/IIIa may be involved in retinal vein occlusion and blocking platelet aggregation may be a new therapeutic approach for retinal vein occlusion.

Collapse

Xu X, Xu S, Zhang Y, Wang L, Yan C, Xu Z, Zhao Q, Qi X. Neutrophil extracellular traps formation may be involved in the association of propranolol with the development of portal vein thrombosis. Thromb Res 2024;238:208-221. [PMID: 38733693 DOI: 10.1016/j.thromres.2024.04.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 04/26/2024] [Accepted: 04/29/2024] [Indexed: 05/13/2024]

Suzuki J, Namisaki T, Takya H, Kaji K, Nishimura N, Shibamoto A, Asada S, Kubo T, Iwai S, Tomooka F, Takeda S, Koizumi A, Tanaka M, Matsuda T, Inoue T, Fujimoto Y, Tsuji Y, Fujinaga Y, Sato S, Kitagawa K, Kawaratani H, Akahane T, Mitoro A, Matsumoto M, Asada K, Yoshiji H. ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis. Int J Mol Sci 2024;25:2678. [PMID: 38473925 PMCID: PMC10931754 DOI: 10.3390/ijms25052678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 02/22/2024] [Accepted: 02/23/2024] [Indexed: 03/14/2024] Open

Abstract

Portal vein thrombosis (PVT), one of the most prevalent hepatic vascular conditions in patients with liver cirrhosis (LC), is associated with high mortality rates. An imbalance between a disintegrin-like metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS-13) enzyme and von Willebrand factor (VWF) is responsible for hypercoagulability, including spontaneous thrombus formation in blood vessels. Herein, we aimed to identify potential prognostic and diagnostic biomarkers in Japanese patients with LC and PVT. In total, 345 patients were divided into two groups: 40 patients who developed PVT (PVT group) and 305 who did not develop PVT (NPVT group). Among the 345 patients with LC, 81% (279/345) were deemed ineligible due to the presence of preventive comorbidities, active or recent malignancies, and organ dysfunction. The remaining 66 patients were divided into two groups: the PVT group (n = 33) and the NPVT group (n = 33). Plasma ADAMTS-13 activity (ADAMTS-13:AC) and the vWF antigen (VWF:Ag) were measured using enzyme-linked immunosorbent assays. Contrast-enhanced, three-dimensional helical computed tomography (CT) was used to detect and characterize PVT. ADAMTS-13:AC was significantly lower in the PVT group than in the NPVT group. No significant differences in plasma vWF:Ag or liver stiffness were observed between the two groups. ADAMTS-13:AC of <18.8 was an independent risk factor for PVT on multivariate analyses (odds ratio: 1.67, 95% confidence interval: 1.21-3.00, p < 0.002). The receiver operating characteristic analysis of ADAMTS-13:AC revealed an area under the curve of 0.913 in PVT detection. Patients with PVT having ADAMTS-13:AC ≥18.8 (n = 17) had higher albumin levels and better prognoses than those with ADAMTS-13:AC <18.8 (n = 16). No significant correlations of ADAMTS-13:AC levels with either fibrin degradation product or D-dimer levels were observed. ADAMTS-13:AC levels could be potential diagnostic and prognostic biomarkers for PVT in Japanese patients with LC.

Collapse

Affiliation(s)

Junya Suzuki Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Tadashi Namisaki Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Hiroaki Takya Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Kosuke Kaji Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Norihisa Nishimura Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Akihiko Shibamoto Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Shohei Asada Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Takahiro Kubo Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Satoshi Iwai Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Fumimasa Tomooka Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Soichi Takeda Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Aritoshi Koizumi Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Misako Tanaka Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Takuya Matsuda Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Takashi Inoue Department of Evidence-Based Medicine, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan;
Yuki Fujimoto Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Yuki Tsuji Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Yukihisa Fujinaga Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Shinya Sato Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Koh Kitagawa Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Hideto Kawaratani Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Takemi Akahane Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Akira Mitoro Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)
Masanori Matsumoto Department of Hematology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan;
Kiyoshi Asada Clinical Research Center, Nara Medical University, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan;
Hitoshi Yoshiji Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan; (J.S.); (H.T.); (K.K.); (A.S.); (S.A.); (T.K.); (S.I.); (F.T.); (S.T.); (A.K.); (M.T.); (T.M.); (Y.F.); (Y.T.); (Y.F.); (S.S.); (H.K.); (T.A.); (A.M.); (H.Y.)

Collapse

High plasma soluble thrombomodulin levels indicated poor prognosis of decompensated liver cirrhosis: a prospective cohort study. Eur J Gastroenterol Hepatol 2022;34:1140-1146. [PMID: 35946457 PMCID: PMC9528942 DOI: 10.1097/meg.0000000000002428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]

Odriozola A, Puente Á, Cuadrado A, Rivas C, Anton Á, González FJ, Pellón R, Fábrega E, Crespo J, Fortea JI. Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review. J Clin Med 2022;11:6435. [PMID: 36362663 PMCID: PMC9655000 DOI: 10.3390/jcm11216435] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 10/26/2022] [Accepted: 10/28/2022] [Indexed: 08/06/2023] Open

Affiliation(s)

Aitor Odriozola Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Ángela Puente Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Antonio Cuadrado Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Coral Rivas Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Ángela Anton Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Francisco José González Radiology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Raúl Pellón Radiology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Emilio Fábrega Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain
Javier Crespo Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain
José Ignacio Fortea Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain

Collapse

Tissue-Type Plasminogen Activator-Inhibitor Complex as an Early Predictor of Septic Shock: A Retrospective, Single-Center Study. DISEASE MARKERS 2022;2022:9364037. [PMID: 35401879 PMCID: PMC8984737 DOI: 10.1155/2022/9364037] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Revised: 02/28/2022] [Accepted: 03/08/2022] [Indexed: 11/17/2022]

Abstract

Background

Sepsis can progress to septic shock and death, and identifying biomarkers of this progression may permit timely intervention to prevent it. This study explored whether levels of tissue-type plasminogen activator-inhibitor complex (t-PAIC) in serum can predict septic shock early.

Methods

We retrospectively analyzed 311 sepsis patients who had been admitted to the intensive care unit (ICU) at our tertiary care hospital between May 2018 and April 2021, and we divided them into those who progressed to septic shock (n = 203) or not (n = 108) based on sepsis-3 definition. After matching patients in the two groups based on propensity scoring, we screened for risk factors of septic shock using logistic regression. We assessed potential predictors of such shock based on the area under the receiver-operating characteristic curve (AUC), Kaplan-Meier survival curves, and correlation analysis.

Results

After propensity score matching to generate two equal groups of 108 patients, we found that serum t-PAIC was significantly higher in septic shock patients. Uni- and multivariate logistic regression identified t-PAIC as an independent risk factor for septic shock (OR 1.14, 95% CI 1.09–1.19, P < 0.001) and a biomarker that predicted it with an AUC up to 0.875 (95% CI, 0.829-0.920). Based on the optimal cut-off of t‐PAIC = 17.9 ng/mL, we found that patients at or above this threshold had significantly higher lactate levels and scores on the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA). Such patients also had significantly worse survival (HR 2.4, 95% CI 1.38–4.34, P = 0.004). Spearman's correlation coefficients were 0.66 between t-PAIC and lactate, and 0.52 between t-PAIC and SOFA.

Conclusions

Serum levels of t-PAIC may be an independent risk factor for septic shock, and they may correlate with the severity of such shock.

Collapse

Lirong T, Minmin X, Manqiu Y, Yanping L. Performance evaluation of thrombus molecular markers thrombomodulin, thrombin-antithrombin complex, plasmin-α2-plasmin inhibitor complex, and tissue plasminogen activator-inhibitor complex by a chemiluminescence analyzer. Hippokratia 2022;26:78-82. [PMID: 37188051 PMCID: PMC10177852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]

The Pathophysiology of Portal Vein Thrombosis in Cirrhosis: Getting Deeper into Virchow's Triad. J Clin Med 2022;11:jcm11030800. [PMID: 35160251 PMCID: PMC8837039 DOI: 10.3390/jcm11030800] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 01/21/2022] [Accepted: 01/28/2022] [Indexed: 02/07/2023] Open

Zenlander R, Havervall S, Magnusson M, Engstrand J, Ågren A, Thålin C, Stål P. Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma. Sci Rep 2021;11:18025. [PMID: 34504150 PMCID: PMC8429678 DOI: 10.1038/s41598-021-97233-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Accepted: 08/20/2021] [Indexed: 12/20/2022] Open

Abstract

Neutrophil extracellular traps (NETs) are web-like structures consisting of DNA, histones and granule proteins, released from neutrophils in thrombus formation, inflammation, and cancer. We asked if plasma levels of the NET markers myeloperoxidase (MPO)-DNA and citrullinated histone H3 (H3Cit)-DNA, are elevated in liver cirrhosis and hepatocellular carcinoma (HCC) and if the levels correlate with clinical parameters. MPO-DNA, H3Cit-DNA, and thrombin–antithrombin (TAT) complex, as a marker of coagulation activity, were measured using ELISA in plasma from 82 patients with HCC, 95 patients with cirrhosis and 50 healthy controls. Correlations were made to clinical parameters and laboratory data and patients were followed for a median of 22.5 months regarding thrombosis development. H3Cit-DNA was significantly (p < 0.01) elevated in plasma from cirrhosis (66.4 ng/mL) and HCC (63.8 ng/mL) patients compared to healthy controls (31.8 ng/mL). TAT levels showed similar pattern (3.1, 3.7, and 0.0 µg/mL respectively, p < 0.01). MPO-DNA was significantly (p < 0.01) elevated in cirrhosis patients (0.53 O.D.) as compared to controls (0.33 O.D.). Levels of MPO-DNA and H3Cit-DNA correlated positively with Child–Pugh and MELD score. TAT was increased in all Child–Pugh and MELD groups. In multivariable logistic regression, Child B and C liver cirrhosis were independent predictors of elevated H3Cit-DNA in plasma. Levels of MPO-DNA and H3Cit-DNA were similar in patients with or without history of thrombosis, or thrombus formation during follow-up. In conclusion, plasma markers of NET formation are elevated in liver cirrhosis and correlate to the degree of liver dysfunction in patients with liver cirrhosis and/or HCC. The presence of HCC did not further increase the plasma levels of NET markers as compared to patients with cirrhosis only.

Collapse